About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals, Inc. - Common Stock (NQ:CTXR)

0.8480 -0.0020 (-0.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Citius Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15% ↗
Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million registered direct offering. 
Via Benzinga
News headline image
This Pharma Company Is Preparing To Launch Its Lead Candidate
This Pharma Company Is Preparing To Launch Its Lead Candidate 
Via News Direct
News headline image
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks have an unusual volume in today's session ↗
Volume analysis on 2025-04-01: stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Monday's session: top gainers and losers ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday ↗
 
Via Benzinga
News headline image
US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking ↗
U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade. 
Via Benzinga
News headline image
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday ↗
 
Via Benzinga
News headline image
Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
US Stocks Mixed; Best Buy Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024 ↗
CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
News headline image
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection ↗
Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refractory cutaneous T-cell lymphoma. U.S. market launch planned within five... 
Via Benzinga
News headline image
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology 
Via News Direct
News headline image
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products 
Via News Direct
News headline image
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second... 
Via Newsfile
News headline image
Analysts Hunt for Undervalued Biotech Stocks
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first... 
Via Newsfile
Topics Economy Initial Public Offering
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
Via AB Newswire
News headline image
Bloodstream Infections - From Threats to Solutions
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second... 
Via Newsfile
Topics Death
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
Via AB Newswire
News headline image
Biopharma Stocks Transformative Innovation for the Future of Health
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first... 
Via Newsfile
Topics Artificial Intelligence
News headline image
Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections ↗
Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infections, show significant improvement in time to catheter failure and overall... 
Via Benzinga
News headline image
Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue ↗
Yogi Tea recalls are in effect for some of the company's tea bags over concerns of pesticide residue that may be found in them. 
Via InvestorPlace
Topics Product Recall
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.